The efficacy and safety of paclitaxel or docetaxel combined with nedaplatin in the neoadjuvant chemotherapy of cervical cancer

Objective:To evaluate the efficacy and safety of the neoadjuvant chemotherapy of paclitaxel or docetaxel combined with nedaplatin in stage Ⅰb2~Ⅱb cervical cancer.Methods:A total of 48 patients with stageⅠb2~Ⅱb cervical cancer diagnosed by pathology were investigated,and divided into the paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group(24 cases each group).The paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were treated with neoadjuvant chemotherapy for 1 cycle before radical hysterectomy and radical radiation therapy,respectively.The clinical effect and adverse reaction between two groups were compared.Results:The total effective rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 83.33% and 79.17%,respectively,and the difference of which was not statistically significant(P>0.05).The complete remission rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 29.17% and 16.67%,respectively,and the difference of which was not statistically significant(P>0.05).The excision rate in two groups was 100%.The incidence rates of high risk factors of postoperative adverse prognosis in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 33.33% and 16.67%,respectively.The 3-year free tumor survival rates and overall survival rates in paclitaxel plus nedaplatin group and docetaxel plus nedaplatin group were 91.67% ＆ 95.83% and 87.50% ＆ 95.83%,respectively,and the differences of which were not statistically significant(P>0.05).The difference of the total incidence rate of adverse reaction between two groups was not statistically significant(P>0.05).Conclusions:The neoadjuvant chemotherapy of paclitaxel or docetaxel combined with nedaplatin in stage Ⅰb2~Ⅱb cervical cancer is safe and effective.The clinical effect and adverse reaction of two methods are similar,and patients can tolerate.